Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026Business Wire • 09/18/26
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 09/17/26
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two YearsBusiness Wire • 09/17/26
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 09/16/26
How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?24/7 Wall Street • 09/12/26
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 09/10/26
Here are the stocks to favor in the fourth quarter — and those you should avoidMarket Watch • 09/10/26
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 09/10/26
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?Zacks Investment Research • 09/09/26
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene AutoleucelBusiness Wire • 09/08/26
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?Zacks Investment Research • 09/04/26
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental researchWSJ • 09/03/26
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026Business Wire • 08/29/26
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise InvestorsThe Motley Fool • 08/29/26